Evommune
Evommune, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel treatments for immune-mediated inflammatory diseases. The company is advancing innovative therapies, such as EVO756 and EVO301, aimed at addressing symptoms and halting disease progression. Their goal is to provide new treatment options for patients suffering from chronic inflammatory conditions.
Buy Funded Startups lists
Funding Round: Series C
Funding Amount: $115M
Date: 31-Oct-2024
Investors: RA Capital Management, Sectoral Asset Management, B Capital, Marshall Wace, Avego Bioscience Capital, Longwood Fund, RTW Investments, ADAR1 Capital Management, NEXTBio Capital, Beiersdorf Venture Capital, FemHealth Ventures, Allostery Investments LP, Pivotal bioVenture Partners, EQT Life Sciences, Andera Partners, Amplitude Ventures, SymBiosis, Verition Fund Management
Markets: Biotechnology, Immunology, Pharmaceuticals, Health Care, Life Science, Drug Discovery
HQ: Palo Alto, California, United States
Founded: 2020
Website: https://www.evommune.com/
LinkedIn: https://www.linkedin.com/company/evommune
Crunchbase: https://www.crunchbase.com/organization/evommune
Leave a Comment
Comments
No comments yet.